Cell-Specific Pharmacology Compounds With HaloTag Covalent Capture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical technologies struggle to achieve cell-specific delivery and modulation in complex organ systems like the brain, where drug-receptor interactions are unclear, making it difficult to target specific cell types for mood, anxiety, addiction, psychosis, and motor coordination.
Innovation Solution
Development of compounds with linkers and moieties that allow for cell-specific delivery through the HaloTag Protein (HTP) system, enabling covalent capture and local accumulation of pharmaceutical cargo, enhancing local drug concentration without chemical switches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional pharmacology is used to deliver drugs in complex organ systems like the brain, then drugs can reach target receptors, but cell-specific delivery cannot be achieved and off-target effects occur
Solution Approach 1:
The patent applies local quality by making the drug molecule itself location-specific through the DART technology. The HaloTag ligand portion of the DART molecule binds specifically to HaloTag protein expressed only in target cells, thereby delivering the pharmacological cargo exclusively to those cells. This ensures that different parts of the system (target cells vs. non-target cells) receive different treatments, achieving cell-specific pharmacology without off-target effects.
2Area of stationary object
If drugs are delivered systemically to the brain, then drugs can reach various brain regions, but precise modulation of specific cell types cannot be achieved
Solution Approach 1:
The patent segments the brain into distinct cell type populations by exploiting the selective expression of HaloTag protein in specific cell types. Each cell type expressing HaloTag becomes a discrete target for DART delivery. This segmentation allows systematic targeting of different brain cell populations (neurons, astrocytes, microglia, etc.) using the same DART platform, achieving both broad brain coverage and cell-type specificity.
3Measurement precision
If high local drug concentration is achieved for cell-specific effects, then precise modulation is possible, but complex chemical switches are required
Solution Approach 1:
The patent applies self-service by enabling the target cell to actively recruit the drug to itself through endogenous HaloTag protein expression. The cell's own biological machinery (HaloTag) performs the localization function that would otherwise require complex chemical switches. The DART molecule passively diffuses throughout the brain, and only cells expressing HaloTag can capture and retain the drug, achieving self-directed drug accumulation without external control mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves rapid, thousand-fold cellular specificity, allowing for precise modulation of neurotransmission and safe delivery of even epileptogenic drugs across large brain volumes.
Implementation Method 1
contacting a cell comprising a mutant dehalogenase on a surface of the cell with a compound as disclosed herein, wherein the mutant dehalogenase forms a bond with the compound
Implementation Method 2
Cells of interest can be programmed to express the HaloTag Protein (HTP), providing them a unique ability to covalently capture and locally accumulate the HaloTag Ligand (HTL) along with any conjoined pharmaceutical cargo (Rx)
Data Source
AI summary
Disclosed herein are compounds that have improved cellular specificity. The compounds have linkers and other moieties that can both aid in cellular specificity and that can attach functional groups to a target cell. The compounds can be used, e.g., in methods of modulating, detecting, and labeling of proteins and cells. An example method includes the compound forming a covalent bond with a dehalogenase variant.